NO310443B1 - Farmasöytisk preparat med analgetisk aktivitet og farmasöytisk doseringsform - Google Patents
Farmasöytisk preparat med analgetisk aktivitet og farmasöytisk doseringsform Download PDFInfo
- Publication number
- NO310443B1 NO310443B1 NO19942343A NO942343A NO310443B1 NO 310443 B1 NO310443 B1 NO 310443B1 NO 19942343 A NO19942343 A NO 19942343A NO 942343 A NO942343 A NO 942343A NO 310443 B1 NO310443 B1 NO 310443B1
- Authority
- NO
- Norway
- Prior art keywords
- ibuprofen
- preparation
- pharmaceutical
- arginine
- mixture
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 12
- 239000002552 dosage form Substances 0.000 title claims description 9
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 46
- 239000004475 Arginine Substances 0.000 claims description 17
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 17
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 9
- 239000007938 effervescent tablet Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 description 49
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 18
- 229960001680 ibuprofen Drugs 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 235000009697 arginine Nutrition 0.000 description 14
- 230000001133 acceleration Effects 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 150000001483 arginine derivatives Chemical class 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 108010011485 Aspartame Proteins 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000000605 aspartame Substances 0.000 description 5
- 235000010357 aspartame Nutrition 0.000 description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 5
- 229960003438 aspartame Drugs 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 3
- NTJPVVKEZMOHNU-UHFFFAOYSA-N 6-(oxan-4-yl)-1h-indazole Chemical compound C1COCCC1C1=CC=C(C=NN2)C2=C1 NTJPVVKEZMOHNU-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000019321 monosodium tartrate Nutrition 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 229940119126 sodium bitartrate Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- -1 Propyl parahydroxybenzoic acid Chemical compound 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 244000235659 Rubus idaeus Species 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000008368 mint flavor Substances 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- UQKAOOAFEFCDGT-UHFFFAOYSA-N n,n-dimethyloctan-1-amine Chemical compound CCCCCCCCN(C)C UQKAOOAFEFCDGT-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000002050 international nonproprietary name Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT93MI001325A IT1264856B1 (it) | 1993-06-21 | 1993-06-21 | Composizione farmaceutica ad attivita' analgesica |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO942343D0 NO942343D0 (ja) | 1994-06-20 |
| NO942343L NO942343L (no) | 1994-12-22 |
| NO310443B1 true NO310443B1 (no) | 2001-07-09 |
Family
ID=11366436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19942343A NO310443B1 (no) | 1993-06-21 | 1994-06-20 | Farmasöytisk preparat med analgetisk aktivitet og farmasöytisk doseringsform |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US5500226A (ja) |
| JP (1) | JPH07101855A (ja) |
| BE (1) | BE1007194A3 (ja) |
| CA (1) | CA2125643C (ja) |
| CH (1) | CH687850A5 (ja) |
| DE (1) | DE4420856A1 (ja) |
| DK (1) | DK174687B1 (ja) |
| ES (1) | ES2099021B1 (ja) |
| FR (1) | FR2706892B1 (ja) |
| GB (1) | GB2279250B (ja) |
| HU (1) | HU211669A9 (ja) |
| IT (1) | IT1264856B1 (ja) |
| NL (1) | NL193820C (ja) |
| NO (1) | NO310443B1 (ja) |
| SE (1) | SE9402157L (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264856B1 (it) * | 1993-06-21 | 1996-10-17 | Zambon Spa | Composizione farmaceutica ad attivita' analgesica |
| US5654334A (en) * | 1995-06-23 | 1997-08-05 | Oklahoma Medical Research Foundation | Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester |
| US5707967A (en) * | 1995-10-27 | 1998-01-13 | Vanmoor; Arthur | Pain relief compositions |
| CA2266098A1 (en) * | 1996-09-26 | 1998-04-02 | Oklahoma Medical Research Foundation | Use of n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester and its derivatives in disease regression |
| AU3221599A (en) | 1998-04-03 | 1999-10-25 | Daily Wellness Company, The | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation |
| IT1301966B1 (it) * | 1998-07-30 | 2000-07-20 | Zambon Spa | Composizioni farmaceutiche ad attivita' analgesica |
| KR100523242B1 (ko) * | 2000-05-18 | 2005-10-24 | 한미약품 주식회사 | 이부프로펜을 함유하는 정제 조성물 |
| AU2002258013A1 (en) * | 2001-04-10 | 2002-10-28 | Fakhreddin Jamali | Animal model for evaluating analgesics |
| US6727286B2 (en) | 2001-11-02 | 2004-04-27 | Cumberland Pharmaceuticals Inc. | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
| US20050137262A1 (en) * | 2003-12-22 | 2005-06-23 | Hu Patrick C. | Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses |
| KR100678837B1 (ko) | 2005-01-03 | 2007-02-05 | 한미약품 주식회사 | 활성 성분으로 덱시부프로펜을 함유하는 시럽제 조성물 및그의 제조 방법 |
| KR100730393B1 (ko) | 2005-06-10 | 2007-06-20 | 한국콜마 주식회사 | 이부프로펜 및 아르기닌을 함유하는 약학 조성물의제조방법 |
| ES2303468B1 (es) * | 2007-01-22 | 2009-06-08 | Masterfarm, S.L | "una composicion farmaceutica pulverulenta que comprende ibuprofeno". |
| MX2010004974A (es) * | 2010-05-04 | 2011-11-23 | Senosiain S A De C V Lab | Combinacion de un aine y un aminoacido. |
| KR101890649B1 (ko) * | 2013-07-30 | 2018-09-28 | 라이온 가부시키가이샤 | 정제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1209667B (it) * | 1985-11-12 | 1989-08-30 | Zambon Spa | Composizione effeverscente adattivita' analgesica. |
| IT1197038B (it) * | 1986-08-01 | 1988-11-25 | Zambon Spa | Composizione farmaceutica ad attivita' analgesica |
| DE3639038C2 (de) * | 1986-11-14 | 1997-02-06 | Helmut Dr Lukas | Verwendung von S-(+)-Ibuprofen zur schnellen Behandlung humaner Schmerzen |
| US4851444A (en) * | 1987-07-10 | 1989-07-25 | Analgesic Associates | Onset-hastened/enhanced analgesia |
| US5262179A (en) * | 1989-09-13 | 1993-11-16 | Nicholas Kiwi Pty Ltd. | Non-effervescent ibuprofen compositions |
| DE69022678T2 (de) * | 1989-10-17 | 1996-03-21 | Merck & Co Inc | S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential. |
| IT1264856B1 (it) * | 1993-06-21 | 1996-10-17 | Zambon Spa | Composizione farmaceutica ad attivita' analgesica |
-
1993
- 1993-06-21 IT IT93MI001325A patent/IT1264856B1/it active IP Right Grant
-
1994
- 1994-05-20 BE BE9400520A patent/BE1007194A3/fr not_active IP Right Cessation
- 1994-05-30 CH CH01671/94A patent/CH687850A5/it not_active IP Right Cessation
- 1994-05-31 GB GB9410898A patent/GB2279250B/en not_active Expired - Lifetime
- 1994-06-03 FR FR9406818A patent/FR2706892B1/fr not_active Expired - Lifetime
- 1994-06-07 US US08/255,776 patent/US5500226A/en not_active Expired - Lifetime
- 1994-06-10 CA CA002125643A patent/CA2125643C/en not_active Expired - Lifetime
- 1994-06-15 DE DE4420856A patent/DE4420856A1/de not_active Ceased
- 1994-06-20 NL NL9401005A patent/NL193820C/nl not_active IP Right Cessation
- 1994-06-20 NO NO19942343A patent/NO310443B1/no not_active IP Right Cessation
- 1994-06-20 DK DK199400725A patent/DK174687B1/da active
- 1994-06-20 ES ES09401335A patent/ES2099021B1/es not_active Expired - Fee Related
- 1994-06-20 SE SE9402157A patent/SE9402157L/xx not_active Application Discontinuation
- 1994-06-20 JP JP6136834A patent/JPH07101855A/ja active Pending
-
1995
- 1995-06-27 HU HU95P/P00467P patent/HU211669A9/hu unknown
- 1995-10-27 US US08/549,206 patent/US5645857A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| BE1007194A3 (fr) | 1995-04-18 |
| NO942343D0 (ja) | 1994-06-20 |
| CA2125643C (en) | 2007-09-04 |
| HU211669A9 (en) | 1995-12-28 |
| CA2125643A1 (en) | 1994-12-22 |
| DE4420856A1 (de) | 1994-12-22 |
| SE9402157D0 (sv) | 1994-06-20 |
| CH687850A5 (it) | 1997-03-14 |
| GB2279250B (en) | 1998-02-25 |
| ITMI931325A0 (it) | 1993-06-21 |
| SE9402157L (sv) | 1994-12-22 |
| FR2706892B1 (ja) | 1995-10-20 |
| NL9401005A (nl) | 1995-01-16 |
| NO942343L (no) | 1994-12-22 |
| ITMI931325A1 (it) | 1994-12-21 |
| JPH07101855A (ja) | 1995-04-18 |
| NL193820C (nl) | 2000-12-04 |
| US5500226A (en) | 1996-03-19 |
| US5645857A (en) | 1997-07-08 |
| DK72594A (da) | 1994-12-22 |
| NL193820B (nl) | 2000-08-01 |
| DK174687B1 (da) | 2003-09-15 |
| GB2279250A (en) | 1995-01-04 |
| ES2099021B1 (es) | 1998-01-16 |
| GB9410898D0 (en) | 1994-07-20 |
| FR2706892A1 (ja) | 1994-12-30 |
| IT1264856B1 (it) | 1996-10-17 |
| ES2099021A1 (es) | 1997-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL193307C (nl) | Bruispreparaat met analgetische werkzaamheid. | |
| NO310443B1 (no) | Farmasöytisk preparat med analgetisk aktivitet og farmasöytisk doseringsform | |
| AU2005282135B2 (en) | Method of enhancing absorptions of transmucosal administration formulations | |
| NL194031C (nl) | Farmaceutische samenstelling met een analgetische werking en daaruit met geschikte excipiÙntia gevormd granulaat. | |
| RU2720204C1 (ru) | Сублингвальная фармацевтическая композиция эдаравона и (+)-2-борнеола | |
| SK4862002A3 (en) | Extended release formulations of erythromycin derivatives | |
| BR112012028035A2 (pt) | forma de dosagem e formulação de liberação imediata, e, uso das mesmas | |
| JP2001527546A (ja) | 舌下又は頬投与によって送達される薬物の徐放 | |
| NZ555120A (en) | Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition | |
| RU2505286C1 (ru) | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения | |
| CA2889283C (en) | Prolonged-release diphenidol composition | |
| EP2393478B1 (en) | Taste and odor masked pharmaceutical compositions with high bioavailability | |
| EP2571499A1 (en) | Pharmaceutical composition comprising n- acetylcysteine and a xanthine | |
| CN105407876B (zh) | 抗结核病的稳定的包含异烟肼颗粒和利福喷汀颗粒的可分散的片剂及其制备方法 | |
| US20240009133A1 (en) | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs | |
| US20200069675A1 (en) | Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain | |
| NO333977B1 (no) | Oromukosalpreparat og fremgangsmåte for fremstilling derav. | |
| RU2795085C2 (ru) | Дозированная форма с немедленным высвобождением | |
| AU2018440280B2 (en) | Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain | |
| KR100523242B1 (ko) | 이부프로펜을 함유하는 정제 조성물 | |
| RU2627611C2 (ru) | Противотуберкулезная фармацевтическая композиция, содержащая тиоацетазон | |
| RU2543322C1 (ru) | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения | |
| KR101584919B1 (ko) | 암로디핀 경구 붕해형 정제용 조성물 및 이의 제조방법 | |
| US20210267955A1 (en) | Low dose oral pharmaceutical composition of pirfenidone or salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |